Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

Importance In the last decade, immune checkpoint inhibitors (ICIs) have been approved for
the treatment of many cancer types. Immune checkpoint inhibitor–associated myocarditis …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …

Background Myocarditis is a potentially fatal complication of immune checkpoint inhibitor
(ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant
numbers of patients with hematological cancers. While these unique immunotherapies have …

MACE independent of age, sex, lowest left ventricular ejection fraction, and time of initiation
(hazard ratio, 0.27 [95% CI, 0.09–0.84]; P= 0.024). Patients receiving corticosteroids within …

Immune checkpoint inhibitors (ICIs) are newer therapies being applied to an increasing
number of patients with cancer. Data suggest that up to 36% of cancer patients may be …